Evaluation of carrier added and no carrier added 90Y-EDTMP as bone seeking therapeutic radiopharmaceutical

The optimum conditions to label ethylenediaminetetramethylene phosphonate (edtmp) compound with 90y as a potential candidate for bone metastases therapy were investigated. yttrium-90 is a pure β-emitter and can be obtained by 89y (n,γ) 90y nuclear reaction in a reactor or from an in-house generator system (90sr→90y). the preparation of 90y-edtmpis described using 90y, which was obtained from neutron irradiation of y2o3 as well as from a laboratory scale organic resin-based 90sr→90y generator. because of the radiolabeling yield of 90y-edtmp on ligand/metal molar ratio, incubation time and ph was evaluated. under optimum parameters, the radiolabeling yields of 90y-edtmpwere <95% for no-carrier-added as well as carrier-added 90y. the biodistribution of no-carrier-added and carrier-added 90yedtmpcomplexes in rats was identical. the results indicate that 90y (carrier-added)-edtmp is also an effective bone pain palliation agent because of its rapid blood clearance, greater uptake in bones and little absorption in soft tissues.